Skip to main content

news

Shardul Amarchand Mangaldas & Co. and Goodwin Procter have advised Biocon Biologics, a subsidiary of Indian drugmaker Biocon, in its $3.34 billion acquisition of the biosimilars business of U.S.-based Viatris, which was counseled by Cravath, Swaine & Moore, and Saraf and Partners.

According to Reuters, the deal will expand Biocon's biosimilars portfolio of 20 treatments by adding therapies used for treating diabetes, tumors and autoimmune diseases and commercialising them for developed markets.

Viatris will get up to $2.34 billion in cash, and convertible shares in Biocon Biologics worth $1 billion, Reuters added.

The SAM team was led by partners Iqbal Khan and Ambarish, while the Goodwin Procter team was led by partners Graham Defries and Michael R. Patrone. Partner Mohit Saraf led the Saraf and Partners team, while the Cravath team was led by partners Mark Greene and Aaron Gruber.

Related Articles

Deals

Trilegal, Khaitan guide RMZ-Colt $1.7 bln India data centre JV

by Nimitt Dixit |

Trilegal advised Indian alternative asset owner RMZ Group on its $1.7 billion joint venture with Colt Data Centre Services, which was advised by Khaitan & Co, to invest in the Indian data centre market, as well as the proposed acquisition of stakes in two data centre projects.

Deals

HSF, CC lead on SF Holdings’ $750 mln Hong Kong IPO

by Hu Yangxiaoxiao 胡阳潇潇 |

Herbert Smith Freehills, CM Law Firm, and Grandall Law Firm have advised Chinese logistics provider SF Holdings on its $750 million initial public offering in Hong Kong, with Clifford Chance and King & Wood Mallesons advising the joint sponsors.

Deals

Bakers, HSF act on PE acquisition of Japan’s jinjer

by Nimitt Dixit |

Baker & McKenzie (Gaikokuho Joint Enterprise) has advised private equity firms J-STAR Co and Potentia Capital on their joint acquisition of jinjer, one of Japan’s leading HR SaaS players. While financial terms were not recorded, news reports value the deal at $500 million.